Sum Up The Parts: The Health Care Select Sector SPDR Fund ETF Could Be Worth $102


Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.  For the Health Care Select Sector SPDR Fund ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $102.19 per unit.

With XLV trading at a recent price near $80.70 per unit, that means that analysts see 26.63% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XLV’s underlying holdings with notable upside to their analyst target prices are Illumina, Thermo Fisher Scientific and Zoetis. Although ILMN has traded at a recent price of $272.46/share, the average analyst target is 30.92% higher at $356.69/share. Similarly, TMO has 27.68% upside from the recent share price of $208.47 if the average analyst target price of $266.17/share is reached, and analysts on average are expecting ZTS to reach a target price of $101.00/share, which is 27.40% above the recent price of $79.28.

Combined, ILMN, TMO, and ZTS represent 5.23% of the Health Care Select Sector SPDR Fund ETF. Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
Health Care Select Sector SPDR Fund ETF XLV $80.70 $102.19 26.63%
Illumina Inc ILMN $272.46 $356.69 30.92%
Thermo Fisher Scientific Inc TMO $208.47 $266.17 27.68%
Zoetis Inc ZTS $79.28 $101.00 27.40%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock’s trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.